Spring Creek Capital’s Gilead Sciences GILD Stock Holding History

Spring Creek Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-17,380	Closed	-$1.23M	–	283
2018 Q2	$1.23M	Buy	+17,380	New	+$1.23M	0.14%	79

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Spring Creek Capital's GILD Position: Q3 2018 in Review

Spring Creek Capital sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 17,380 shares — an estimated $1.23M sold.

Spring Creek Capital first reported a position in GILD in Q2 2018 and held it in 1 quarter. The position peaked at $1.23M in Q2 2018. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Spring Creek Capital reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
Spring Creek Capital sold 17,380 Gilead Sciences shares in Q3 2018, an estimated $1.23M.
Spring Creek Capital first reported a position in Gilead Sciences in Q2 2018 and held it in 1 quarter.
Spring Creek Capital's Gilead Sciences position peaked at $1.23M in Q2 2018.
1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Spring Creek Capital's 13F filing for Q3 2018, filed 13 Nov 2018.